CPC Organization Department and NHC Issue Revised Management Measures for Public Hospital Leadership – Eight‑Chapter Framework Resets Qualifications, Terms, Assessment and Exit Rules Nationwide

Beijing, China – 12 Aug 2026 – The Organization Department of the CPC Central Committee and China’s National Health Commission (NHC) promulgated the revised Management Measures for Leaders in Public Medical Institutions (originally enacted 13 Jan 2017; revised 22 Jul 2026), an eight‑chapter, 35‑article regulation governing the selection, tenure, assessment, incentives, supervision and exit of leadership teams in public hospitals — effective from the date of publication and publicly released via China Organization and Personnel News on 18 Sep 2026.

Policy Snapshot

ItemDetail
AuthoritiesOrganization Department of the CPC Central Committee; National Health Commission (NHC)
DocumentManagement Measures for Leaders in Public Medical Institutions (2026 revision)
Revision HistoryEnacted 13 Jan 2017 (Organization Dept + former NHFPC); revised 22 Jul 2026; published 12 Aug 2026
ScopeLeadership team members of public hospitals run by governments at county level and above, public institutions, social groups and other social organizations; SOE‑run public hospitals apply the measures by reference
Structure8 chapters, 35 articles – general provisions, qualifications, selection & appointment, assessment, career development & incentives, supervision, exit, supplementary provisions
Effective DateFrom date of publication (12 Aug 2026)

Qualification & Selection Framework

  • Baseline Qualifications: Generally a bachelor’s degree or above; 5+ years of medical/health or related management experience — 10+ years for leaders of tertiary hospitals; deputy‑to‑principal promotion requires 2+ years in a deputy role, and lower‑principal to higher‑deputy requires 3+ years.
  • Technical‑to‑Management Tracks: Professionals from medical, pharmacy, nursing, technical and research posts must hold corresponding professional technical appointments — e.g., senior or 5+ years associate‑senior titles for Grade 4+ management posts and for tertiary hospital presidents and business‑line deputies; relaxed thresholds apply in hardship and remote areas.
  • Sourcing Channels: Selection generally via internal recommendation or external dispatch, with competitive appointment and open recruitment permitted to widen the talent pool; presidents and business deputies generally come from the medical/health sector.
  • Appointment Modes: Tenure by election, appointment or engagement (聘任制) — leaders produced through open selection generally serve under the engagement system, with flexible pay and term arrangements allowed.

Tenure, Assessment & Compensation

  • Term Limits: Terms of 3–5 years; continuous service in the same post generally capped at 10 years (extendable with approval); leaders are expected to serve out at least one full term.
  • Public‑Welfare‑Oriented Targets: Term objectives embed medical quality and safety, cost control, public‑welfare duties, lawful management, medical ethics and Party building; tertiary hospitals add digital‑intelligent construction and discipline/team development; TCM hospitals must reflect traditional Chinese medicine’s distinctive advantages.
  • Assessment Ratings: Teams graded excellent/good/average/poor (excellent ≤ 30 % of teams assessed); individuals graded excellent/qualified/basically qualified/unqualified (excellent ≤ 25 %), with cascading caps when a team is rated average or poor.
  • Time Commitment & Pay: Leaders must devote ≥ 4/5 of statutory working time to hospital management; compensation ties to assessment and keeps a reasonable ratio to average staff income — directly linking leader income to hospital economic revenue is strictly prohibited, with an annual salary system permitted where conditions allow.
  • Development & Rotation: Full training coverage every 5 years; structured exchanges across hospital tiers and regions — urban tertiary hospitals with county hospitals, eastern with central/western institutions — aligned with Healthy China resource‑balancing goals.

Supervision, Recusal & Exit

  • Expanded Oversight: Inspection tours and audits target procurement, drugs and devices, infrastructure, service outsourcing, medical insurance fund use, income distribution, title appointments and “ghost payroll” issues, alongside democratic centralism and “three majors and one large” decision‑making compliance.
  • Recusal Rules: Leaders must recuse themselves where interests involve directly supervised graduate students, their own academic teams or other conflicts affecting impartial duty.
  • Exit Mechanisms: Age‑limit retirement with possible extension for outstanding principals; adjustment of leaders deemed unfit for current posts (e.g., medical ethics violations, poor handling of major emergencies); a resignation system explicitly guards against “revolving door” and “escape‑style resignation” problems, while exiting leaders may transition to professional technical roles.

Market Impact & Outlook

  • Professionalization of Hospital Management: Engagement‑based appointments, 5‑year training cycles and professional‑track transitions signal a deliberate build‑out of a professional public hospital leadership corps.
  • Anti‑Profit Reinforcement: The hard ban on tying leader pay to hospital revenue strengthens the public‑welfare orientation — constraining volume‑driven revenue behavior with downstream effects on device and drug utilization patterns.
  • Talent Redistribution: Mandatory rotation between tertiary, county, eastern and western hospitals operationalizes the policy goal of expanding and sinking quality medical resources.
  • Compliance Bar Rises: The detailed supervision catalogue raises accountability for hospital leadership — and by extension for suppliers’ interactions with procurement, IT and infrastructure decision‑makers.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding implementation of the revised management measures, including leadership selection, assessment outcomes and compensation reforms. Actual execution depends on interpretation by the Organization Department and NHC, local implementation rules and individual institutional practice, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/wjw/mtbd/202609/7e830145ff3144d8b8609b5616c09793.shtml

Shanxi Healthcare Security Bureau to Implement National TCM Alliance Fourth Batch and Second Batch Follow‑up VBP Results From Oct 15 – Province‑Wide Execution Through 2028 With Listing Suspensions and Price Risk Flags for Non‑Winning Products

Taiyuan, China – 17 Sep 2026 – The Shanxi Provincial Healthcare Security Bureau (Jin Yi Bao Han [2026] No. 72) notified that, effective 15 October 2026, the province will uniformly implement the winning results of the National Traditional Chinese Patent Medicines (TCM) Procurement Alliance’s Fourth Batch centralized procurement (ZCYLM‑2026‑1) and Second Batch follow‑up procurement (ZCYLM‑2026‑2), covering all public medical institutions — including military hospitals — plus participating insurance‑designated private institutions and pharmacies, under a procurement cycle running to 31 December 2028.

Implementation Snapshot

ItemDetail
AuthorityShanxi Provincial Healthcare Security Bureau, China
DocumentJin Yi Bao Han [2026] No. 72 – Notice on implementing national TCM alliance winning results
BatchesNational TCM Procurement Alliance Fourth Batch (ZCYLM‑2026‑1) and Second Batch follow‑up (ZCYLM‑2026‑2)
Institutional ScopeAll provincial public medical institutions (incl. military), participating insurance‑designated private institutions and designated pharmacies
Execution Date15 October 2026, province‑wide
Procurement Cycle15 Oct 2026 – 31 Dec 2028; first year through 14 Oct 2027; agreements signed annually, renewal volumes in principle no less than prior year
Supply RuleWinning enterprises supply at winning prices beyond agreed volumes until cycle expiry

Price Execution & Platform Measures

  • Listing & Tripartite Agreements: The provincial drug and device procurement center will list winning products at winning prices and organize tripartite contracts among winning manufacturers, distributors and medical institutions per volume‑based procurement (VBP) rules.
  • Listing Suspensions: Within the same procurement group (administration route), products already listed provincially but not declared in winning enterprises’ “supply lists” will be suspended from listing — except products containing both natural bezoar and natural musk.
  • Price Risk Flags: Non‑winning products, and natural bezoar/musk products outside winning supply lists, will carry price risk warning markers on the platform.

Usage, Assessment & Monitoring Requirements

  • Rational Use Mandate: Medical institutions must prioritize winning products and fulfill agreed volumes, while avoiding concentrated bulk purchasing of winners and any “one‑size‑fits‑all” cutoff of non‑winning products; where winning products force brand switches for patients, dedicated department and staff training plus patient explanation work is required.
  • Assessment Design: Winning‑product procurement and use enter institutional performance assessments; non‑winning products priced below the lowest winning price are excluded from execution assessment; drug volumes in special‑need and international medical services (outside basic insurance payment) are excluded from monitoring; same‑name/dosage/specification products of one winning enterprise with compliant price differentials across package sizes may be assessed on a merged basis — a rule extendable to other national TCM alliance batches.
  • Supply & Compliance Monitoring: Insurance departments will monitor winning‑enterprise supply and hospital execution, using reminders and accountability interviews for supply shortfalls, with escalation reporting for major quality or supply problems; institutions showing below‑schedule progress, markedly low winning‑product share, or “buying high, not low” will face notification, with further measures for inadequate rectification.
  • Policy Coordination: Procurement, supply assurance, payment settlement, insurance reimbursement and quality management responsibilities are assigned across relevant units to ensure the results take full effect.

Sector Background

  • National TCM Alliance: Led cross‑province centralized procurement of traditional Chinese patent medicines, extending VBP beyond chemical drugs into the TCM segment — one of China’s largest pharmaceutical categories by prescription volume.
  • Follow‑up (接续) Procurement: Successor rounds that re‑tender expiring batch agreements, stabilizing prices and supply continuity for previously procured products.
  • Supply‑List Mechanism: Winning enterprises declare distributable product lists that determine which comparable items remain listed — a lever to steer hospital purchasing toward winners without formally banning alternatives.

Market Impact & Outlook

  • Price Reset for TCM Makers: From 15 October, winning manufacturers gain contracted volume across Shanxi at alliance‑set prices, while non‑winners face platform flags or suspension — reshaping competitive positions per procurement group.
  • Volume Security for Winners: The “winning price applies beyond agreed volumes until cycle end” clause protects hospitals’ upside demand without further negotiation, and annual renewals anchored at no‑less‑than‑prior volumes give winners multi‑year visibility.
  • Compliance Watchpoints: Distributors and manufacturers should verify supply‑list inclusion, prepare tripartite contracts, and track the natural bezoar/musk exemption — the notable carve‑out reflecting scarcity‑driven pricing in premium TCM materials.
  • Replication Signal: The merged‑assessment approach and its extension to other alliance batches may preview softer, more practical execution metrics for TCM VBP nationwide.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of national TCM alliance procurement results in Shanxi, including price adjustments, listing actions and procurement volumes. Actual execution depends on platform operations, enterprise supply performance, institutional compliance and assessment outcomes, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ybj.shanxi.gov.cn/xxfb/xxgkml/202609/t20260918_10222979.html

Guangdong Drug Exchange Center Publishes First September 2026 Batch of Newly Listed Bargaining‑Price Disinfection Products – Batch YJHCGW39‑20260901‑XD Joins Negotiated Procurement Scope for Hospitals Province‑Wide

Guangzhou, China – 17 Sep 2026 – The Guangdong Drug Exchange Center published the products that received no objections during the publicity period in the first batch of September 2026 newly added bargaining‑price listed disinfection products (batch code YJHCGW39‑20260901‑XD), incorporating them into the province’s bargaining‑price listing procurement scope effective immediately, under which medical institutions may procure the products through negotiation at prices no higher than the listed ceiling.

Listing Snapshot

ItemDetail
AuthorityGuangdong Drug Exchange Center (Guangdong Province, China)
PlatformGuangdong Third‑Party Drug Electronic Trading Platform – Medical Consumables Trading System
ActionPublication of newly listed bargaining‑price (议价挂网) disinfection products – first batch, September 2026
BatchYJHCGW39‑20260901‑XD
Publication Date17 September 2026
Product ScopeDisinfection products (消毒产品) declared by enterprises before 10 September 2026, price‑confirmed and listing‑applied via the automatic confirmation workflow; details in the attached product information table
Transaction RuleMedical institutions procure by bargaining at prices not exceeding the listed price

Listing Process & Conditions

  • Automatic Confirmation Workflow: Covered products were declared through the system’s “Price Management – Consumables Bargaining‑Price Listing Addition (Automatic Confirmation Items)” module, where enterprises confirmed price information and submitted listing applications before the 10 September 2026 cut‑off.
  • Publicity‑Period Gate: Only products that received no objections during the publicity period are published in this batch; enterprises are directed to download the attached detailed product list themselves.
  • Deferred Listings: Products with information re‑verification pending or with registration certificates not yet fully effective will be listed only after verification concludes or product status becomes fully effective.
  • Policy Basis: The provincial platform’s announcement on implementing medical consumables listing procurement, the Center’s notice on optimizing routine drug and consumables listing work, and the notice activating the automatic viewing‑and‑confirmation process for bargaining‑price listed consumables price information.

Sector Background

  • Bargaining‑Price Listing (议价挂网): A procurement channel where the listed price serves as a ceiling and hospitals negotiate final prices with suppliers — distinct from fixed‑price centralized procurement, commonly used for competitively supplied consumables and disinfection products.
  • Disinfection Products Category: Managed separately from drugs and medical devices under China’s disinfection product regulations, these products (disinfectants, antiseptics, sanitizing agents for medical use) access hospital channels via provincial platforms once listed.
  • Automation Trend: The automatic price‑confirmation workflow streamlines what was previously manual review — part of Guangdong’s broader digitization of consumables market access with rolling monthly batches.

Market Impact & Outlook

  • Immediate Hospital Access: Products in this batch become procurable across Guangdong’s medical institutions right away, converting listing into commercial opportunity for successful applicants.
  • Price Ceiling Discipline: The “no higher than listed price” bargaining rule anchors hospital negotiations at the confirmed ceiling, reinforcing downward price pressure in the disinfection products segment.
  • Pipeline Watch: Enterprises whose products were held back for re‑verification or pending certificate effectiveness should expect supplementary listings in subsequent batches once conditions are met.
  • Rolling Cadence: The first‑batch numbering (YJHCGW39‑20260901‑XD) reflects a systematic publication schedule — suppliers not in this batch should pre‑position CA credentials, price confirmations and registration documentation ahead of the next monthly cut‑off.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, deferred publication and procurement uptake of bargaining‑price disinfection products in Guangdong. Actual listing status depends on information re‑verification, registration certificate effectiveness and platform processing, and transaction volumes and prices may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100575340429578240